ストックスクリーナーアプリを入手
3.175
6.54%
0.195
アフターアワーズ：
3.17
-0.005
-0.16%
前日終値:
$2.98
開ける：
$2.98
24時間の取引高:
7.13M
Relative Volume:
1.22
時価総額：
$752.69M
収益：
$116.33M
当期純損益:
$-209.25M
株価収益率:
-1.4976
EPS:
-2.12
ネットキャッシュフロー:
$-135.49M
1週間 パフォーマンス:
+1.44%
1か月 パフォーマンス:
-21.41%
6か月 パフォーマンス:
+160.25%
1年 パフォーマンス:
+44.32%
1日の値動き範囲:
$2.97
$3.205
1週間の範囲:
$2.86
$3.205
52週間の値動き範囲:
$0.6925
$4.175
Esperion Therapeutics Inc Stock (ESPR) Company Profile
名前
Esperion Therapeutics Inc
セクター
電話
734-887-3903
住所
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
ESPR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
3.175 | 706.47M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
124.40 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.94 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.33 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.66 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
472.06 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-25 | 開始されました | Piper Sandler | Overweight |
| 2024-12-18 | 開始されました | Goldman | Neutral |
| 2024-12-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-06-20 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-08-01 | アップグレード | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | アップグレード | BofA Securities | Underperform → Buy |
| 2023-03-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-03-16 | ダウングレード | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | 再開されました | BofA Securities | Neutral |
| 2023-02-24 | アップグレード | Jefferies | Hold → Buy |
| 2023-02-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2022-03-10 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-19 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | ダウングレード | Stifel | Buy → Hold |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-02-12 | ダウングレード | Jefferies | Buy → Hold |
| 2021-02-09 | ダウングレード | Goldman | Neutral → Sell |
| 2021-01-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-11-10 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | 再開されました | JP Morgan | Underweight |
| 2020-08-11 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | 再開されました | BofA/Merrill | Buy |
| 2020-03-17 | アップグレード | Citigroup | Neutral → Buy |
| 2020-02-24 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-09-16 | アップグレード | Goldman | Sell → Neutral |
| 2019-05-29 | ダウングレード | Goldman | Neutral → Sell |
| 2019-05-06 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | アップグレード | Goldman | Sell → Neutral |
| 2019-03-13 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-01-07 | 繰り返されました | Needham | Strong Buy |
| 2018-12-13 | 開始されました | Goldman | Sell |
| 2018-10-29 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | 開始されました | BTIG Research | Buy |
| 2018-08-17 | アップグレード | Citigroup | Neutral → Buy |
| 2018-07-11 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-05-02 | ダウングレード | BofA/Merrill | Buy → Underperform |
すべてを表示
Esperion Therapeutics Inc (ESPR) 最新ニュース
Esperion Therapeutics general counsel sells $4.9k in stock By Investing.com - Investing.com Australia
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Esperion Therapeutics general counsel sells $4.9k in stock - Investing.com
Is Esperion Therapeutics Inc. stock a falling knife or bargain buyJuly 2025 Update & Stepwise Trade Signal Guides - bollywoodhelpline.com
Winners Losers: Is Esperion Therapeutics Inc a defensive stockMarket Sentiment Report & Entry and Exit Point Strategies - baoquankhu1.vn
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap DownShould You Sell? - MarketBeat
What is HC Wainwright's Estimate for ESPR FY2025 Earnings? - MarketBeat
Esperion Seeks Acquisitions - marketscreener.com
How does Esperion Therapeutics Inc score in quality rankingsDip Buying & Safe Entry Trade Signal Reports - baoquankhu1.vn
Highs Report: What is Esperion Therapeutics Incs TAM Total Addressable MarketJuly 2025 Sector Moves & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
HC Wainwright Issues Optimistic Estimate for ESPR Earnings - MarketBeat
Esperion Therapeutics Faces Financial Challenges Amid Market Uncertainty - StocksToTrade
Esperion Therapeutics (NASDAQ:ESPR) Shares Down 6.3%Here's Why - MarketBeat
Esperion Projects FY2025 U.S. Net Product Sales Growth Of 35% To 38%; Stock Up - Nasdaq
Esperion Reports $156-$160 Million in 2025 Sales, Unveils Vision 2040 Strategy - Intellectia AI
Esperion reports $156 to $160 million in preliminary full-year 2025 U.S. net product sales - marketscreener.com
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Cholesterol drug maker lays 2040 plan as new pills target 60% LDL drop - Stock Titan
Why Esperion Therapeutics Inc stock attracts global investorsMarket Movers & Community Verified Trade Signals - moha.gov.vn
Esperion Therapeutics Inc. (ESPR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug - MSN
Can Esperion Therapeutics Inc. stock sustain institutional interest2025 Market Sentiment & AI Driven Price Predictions - Улправда
Will Esperion Therapeutics Inc. (0ET) stock beat growth indexesQuarterly Performance Summary & Trade Opportunity Analysis - ulpravda.ru
Is Esperion Therapeutics Inc. (0ET) stock considered safe havenJuly 2025 Chart Watch & Verified Momentum Stock Watchlist - ulpravda.ru
Merger Talk: Is Esperion Therapeutics Inc. (0ET) stock considered safe haven2025 Winners & Losers & Reliable Momentum Entry Alerts - Улправда
Esperion Therapeutics (NASDAQ:ESPR) Sets New 12-Month HighHere's Why - MarketBeat
Esperion Therapeutics gets Untitled Letter from FDA over Nexlizet ad - Medical Marketing and Media
How Esperion Therapeutics Inc. stock performs in rising dollar environmentQuarterly Profit Report & Technical Buy Zone Confirmations - Улправда
Free Technical Research Reports on Biotech Stocks -- Epizyme, Esperion Therapeutics, Exelixis, and Grifols - ADVFN
Will Esperion Therapeutics Inc. (0ET) stock outperform value peersVolume Profile Analysis & Double Digit Returns - Улправда
Esperion Sets Its Sights on New Areas While Maintaining Commitment to Cardiovascular Health - MedCity News
Esperion Therapeutics chief commercial officer sells $277 in stock - MSN
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
What analysts say about Esperion Therapeutics Inc stockMarket Volatility Update & Rapid Wealth Accumulation - earlytimes.in
Why Is Esperion Therapeutics Stock Sinking Premarket Today? - MSN
Esperion Therapeutics (NASDAQ:ESPR) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap UpWhat's Next? - MarketBeat
Is Esperion Therapeutics Inc a good long term investmentGlobal Trade Effects & Free Rapid Wealth Building - earlytimes.in
Esperion Therapeutics (NASDAQ:ESPR) Shares Down 4.8%Time to Sell? - MarketBeat
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
PFE6265887 Bond Coupon Analysis — Rate & Payments - TradingView — Track All Markets
Esperion Therapeutics (NASDAQ:ESPR) Hits New 52-Week HighTime to Buy? - MarketBeat
Is Esperion Therapeutics Inc. stock attractive for long term wealth buildingPortfolio Update Summary & Real-Time Volume Triggers - Улправда
Will Esperion Therapeutics Inc. stock split attract more investorsJuly 2025 Intraday Action & Weekly High Return Stock Forecasts - DonanımHaber
How Esperion Therapeutics Inc. (0ET) stock compares with top peersQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - DonanımHaber
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes - The Manila Times
Esperion's Bempedoic Acid Recognized by ACC as Effective LDL-C Lowering Therapy for Patients with PAD and Diabetes - Quiver Quantitative
Esperion’s Bempedoic Acid Receives Recommendation in 2025 - GlobeNewswire
Take Profit: Will Esperion Therapeutics Inc. stock maintain momentum in 2025 - DonanımHaber
New pill cuts serious limb risks for diabetics with artery disease, ACC says - Stock Titan
Can Esperion Therapeutics Inc. stock hit record highs againJuly 2025 Macro Moves & AI Powered Market Entry Strategies - Улправда
Esperion Therapeutics Inc (ESPR) 財務データ
収益
当期純利益
現金流量
EPS
3.24%
大文字化:
|
ボリューム (24 時間):